Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Liver Transplant

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

At least 4 months post-transplant
Patients in treatment with tacrolimus
Post-transplant diabetes treated with insulin for at least one month

Exclusion criteria

Known hypersensitivity to cyclosporine microemulsion
Investigational drug within 60 days before baseline or during the study
Patients who cannot comply with the study requirements

Other protocol-defined exclusion criteria applied

Treatment and study plan

Cyclosporine microemulsion

Drug

Sponsors and collaborators

Lead sponsor

Novartis

Industry

Registry information

Official study title

Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)

Important dates

Study start: 2004
Primary completion: 2006
Study completion: 2006
First posted: Sep 15, 2005
Registry last updated: Jun 7, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed